


# Respiratory Syncytial Virus Mother and Infant Protection Program (RSV- MIPP) 2026

2 Decision aid to determine if a newborn or child up to 24 months is eligible to receive Beyfortus™ (nirsevimab)



## \*Medical risk conditions

- Preterm birth <32 weeks gestational age
- Haemodynamically significant congenital heart disease
- Significant immunosuppression, such as from malignancy, solid organ transplant, haematopoietic stem cell transplant, or primary immune deficiencies such as severe combined immunodeficiency (SCID)
- Chronic lung disease requiring ongoing oxygen or respiratory support
- Cystic fibrosis with severe lung disease or weight for length <10th percentile
- Neurological conditions that impair respiratory function
- Trisomy 21 or another genetic condition that increases the risk of severe RSV disease

## #Conditions leading to suboptimal RSV antibodies

- Born to mother who received Abrysvo in pregnancy, at time of severe immunosuppression
- Infant received treatment associated with loss of maternal antibodies or treatment after birth dose

## Beyfortus™ (nirsevimab) dose

Infants <5kg = 50mg IM

Infants ≥5kg = 100mg IM

(Weight at presentation)

## Second /subsequent RSV season

2 x 100mg pre-filled syringes at same visit

For further clinical advice, contact the Victorian immunisation hotline 1300 882 924

Option 2: Royal Children's Hospital Immunisation Centre

Option 4: Monash Health Immunisation Service

Report AEFI, including administration error to [SAEFVIC](https://www.saefvic.org.au/)

<<https://www.saefvic.org.au/>>